A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

Launched by ALMIRALL, S.A. · Sep 1, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring how patients with moderate to severe plaque psoriasis feel after switching from their current biologic treatment to a new medication called tildrakizumab. The researchers want to understand the impact of this switch on the patients' skin condition, their quality of life, and the reasons behind their decision to change treatments. The goal is to gather valuable information directly from patients about their experiences before and after making the switch.

To join this study, participants need to be at least 18 years old and currently receiving treatment for their psoriasis with another biologic medication. They might be switching to tildrakizumab because their current treatment isn't working well enough, they have had side effects, or simply because they prefer the new medication for any reason. Participants will be asked to provide feedback on their health and well-being throughout the study. It's important to note that some people may not be eligible, such as those who have had multiple biologic treatments recently or have previously used tildrakizumab.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Written informed consent.
• • 2. \>=18 years of age.
• • 3. Moderate-to-severe plaque psoriasis currently treated with a biologic therapy (TNFα antagonist, IL12/23 antagonist, IL17 antagonist).
• 4. Switch to tildrakizumab due to:
• • 1. primary or secondary treatment failure (PASI \>= 3 or ΔPASI \< 75 and/or DLQI \> 5)
• • 2. adverse events, contraindication, intolerance
• • 3. patient wish (dosing regimen), lack of adherence, or other, including nonmedical reason
• • 5. Treatment with tildrakizumab planned in the frame of clinical practice.
• Exclusion Criteria:
• • 1. Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the Investigator, should not participate in the study.
• • 2. \>=3 previous biologic treatments in the last 3 years.
• • 3. Participation in a clinical trial simultaneous to participation in SW-ATCH.
• • 4. Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance.
• • 5. Patient dependent on the Investigator.
• • 6. Previous treatment with Tildrakizumab.